Aevi Genomic Medicine Inc (NASDAQ:GNMX)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $0.21, but opened at $0.25. Aevi Genomic Medicine shares last traded at $0.24, with a volume of 18988 shares trading hands.
Several equities analysts have commented on the company. JMP Securities downgraded Aevi Genomic Medicine from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 3rd. ValuEngine upgraded Aevi Genomic Medicine from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd.
The company has a market cap of $19.50 million, a price-to-earnings ratio of -0.29 and a beta of 0.58.
A hedge fund recently raised its stake in Aevi Genomic Medicine stock. Vanguard Group Inc grew its stake in Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 1.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 986,590 shares of the biotechnology company’s stock after buying an additional 16,138 shares during the period. Vanguard Group Inc owned 1.52% of Aevi Genomic Medicine worth $1,214,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 19.25% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was originally published by Zolmax and is the sole property of of Zolmax. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://zolmax.com/investing/aevi-genomic-medicine-gnmx-shares-gap-down-to-0-25/3068085.html.
About Aevi Genomic Medicine (NASDAQ:GNMX)
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Featured Story: Fundamental Analysis and Individual Investors
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.